作者
Veronica Yank, C Vaughan Tuohy, Aaron C Logan, Dena M Bravata, Kristan Staudenmayer, Robin Eisenhut, Vandana Sundaram, Donal McMahon, Ingram Olkin, Kathryn M McDonald, Douglas K Owens, Randall S Stafford
发表日期
2011/4/19
来源
Annals of internal medicine
卷号
154
期号
8
页码范围
529-540
出版商
American College of Physicians
简介
Background
Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia, is increasingly used for off-label indications.
Purpose
To evaluate the benefits and harms of rFVIIa use for 5 off-label, in-hospital indications: intracranial hemorrhage, cardiac surgery, trauma, liver transplantation, and prostatectomy.
Data Sources
Ten databases (including PubMed, EMBASE, and the Cochrane Library) queried from inception through December 2010. Articles published in English were analyzed.
Study Selection
Two reviewers independently screened titles and abstracts to identify clinical use of rFVIIa for the selected indications and identified all randomized, controlled trials (RCTs) and observational studies for full-text review.
Data Extraction
Two reviewers …
学术搜索中的文章
V Yank, CV Tuohy, AC Logan, DM Bravata… - Annals of internal medicine, 2011
